2025-08-29 00:58:41
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Lincoln Pharmaceuticals Ltd Q4 FY2023 consolidated PAT slides QoQ to Rs. 12.56 crores
Posted On : 2023-05-25 13:27:13( TIMEZONE : IST )
Lincoln Pharmaceuticals Limited has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 116.3588 crores during the period ended March 31, 2023 as compared to Rs. 140.1238 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 12.5617 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 21.6121 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 6.27 for the period ended March 31, 2023 as compared to Rs. 10.79 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹116.3588 crs | ₹140.1238 crs |  -16.96% |
| Net Profit | ₹12.5617 crs | ₹21.6121 crs | -41.88% |
| EPS | ₹6.27 | ₹10.79 | -41.89% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.116.3588 crores during the period ended March 31, 2023 as compared to Rs.104.4777 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.12.5617 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.11.0241 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.6.27 for the period ended March 31, 2023 as compared to Rs.5.50 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹116.3588 crs | ₹104.4777 crs |  11.37% |
| Net Profit | ₹12.5617 crs | ₹11.0241 crs | 13.95% |
| EPS | ₹6.27 | ₹5.50 | 14.00% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.532.7817 crores during the Financial Year ended March 31, 2023 as compared to Rs.482.1210 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.72.8993 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.69.3552 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.36.40 for the Financial Year ended March 31, 2023 as compared to Rs.34.63 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹532.7817 crs | ₹482.1210 crs | 10.51% |
| Net Profit | ₹72.8993 crs | ₹69.3552 crs | 5.11% |
| EPS | ₹36.40 | ₹34.63 | 5.11% |
Shares of Lincoln Pharmaceuticals Limited was last trading in BSE at Rs. 442.45 as compared to the previous close of Rs. 441.95. The total number of shares traded during the day was 17728 in over 1218 trades.
The stock hit an intraday high of Rs. 456.05 and intraday low of 432.50. The net turnover during the day was Rs. 7889341.00.
